Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2010

p97/VCP at the intersection of the autophagy and the ubiquitin
proteasome system
Jeong-Sun Ju
Washington University School of Medicine in St. Louis

Conrad C. Weihl
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Ju, Jeong-Sun and Weihl, Conrad C., ,"p97/VCP at the intersection of the autophagy and the ubiquitin
proteasome system." Autophagy. 6,2. 283-285. (2010).
https://digitalcommons.wustl.edu/open_access_pubs/2791

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Autophagic Punctum

Autophagic Punctum

Autophagy 6:2, 283-285; February 16, 2010; © 2010 Landes Bioscience

p97/VCP at the intersection of the autophagy and the ubiquitin
proteasome system
Jeong-Sun Ju and Conrad C. Weihl*
Department of Neurology; Washington University School of Medicine; Saint Louis, MO USA

Key words: p97/VCP, autophagy, inclusion body myopathy, IBMPFD, tdp-43
Submitted: 12/14/09
Revised: 12/18/09
Accepted: 12/29/09
Previously published online:
www.landesbioscience.com/journals/
autophagy/article/11063
*Correspondence to: Conrad C. Weihl;
Email: weihlc@neuro.wustl.edu
Punctum to: Jeong-Sun Ju , Rodrigo A.
Fuentealba , Sara E. Miller , Erin Jackson , David
Piwnica-Worms ,Robert H. Baloh , and Conrad
C. Weihl. Valosin-containing protein (VCP) is
required for autophagy and is disrupted in
VCP disease. J Cell Biol 2009; 187:875–88; PMID:
20008565; DOI: 10.1083/jcb.200908115.

www.landesbioscience.com

A feature of aged onset degenerative disease is ubiquitinated protein inclusions.
Similar inclusions are found in different
tissues ranging from the central nervous,
cardiovascular, musculoskeletal and gastrointestinal systems; whether, the same
pathomechanism is responsible for the
similar pathology in these disparate tissues
is not known. To address this question, we
explored the pathogenesis of a multisystem
degenerative disorder, IBMPFD or inclusion body myopathy (IBM), Paget disease
of the bone (PDB) and fronto-temporal
dementia (FTD), of which ubiquitinated
inclusions are a key pathological feature in
muscle, brain and bone tissue. IBMPFD
is caused by mutations in the ubiquitin
proteasome system (UPS) chaperone p97/
VCP. Previous reports suggest dysfunctional UPS in IBMPFD; however, we find
that autophagic protein degradation and
autophagosome maturation are diminished in IBMPFD mutant-expressing
mice, patients and cell models. Moreover,
a loss of p97/VCP function recapitulates
the same effects, suggesting that p97/
VCP is essential for autophagy. Thus, the
degenerative phenotype in IBMPFD and
its phenotypic components (IBM, PDB
and FTD) may be disorders of impaired
autophagy. p97/VCP is likely important
in regulating both UPS- and autophagymediated protein degradation. This places
p97/VCP in a key regulatory position at
the intersection of these two proteolytic
pathways.
The AAA+ (ATPase associated with a
variety of cellular activities) protein p97/
VCP is instrumental in coordinating multiple distinct cellular events. These include
cell division, organelle biogenesis, nuclear
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envelope formation and protein degradation via the UPS. p97/VCP performs these
functions by binding to specific cofactors
that utilize p97/VCP as the “motor” for
each task. Of these processes, mediating
protein degradation is the most critical
for nondividing terminally differentiated
cells such as neurons and skeletal muscle.
Indeed, mutations in p97/VCP cause the
muscle, brain and bone degenerative disorder, IBMPFD. One prominent feature
in IBMPFD patient tissue and transgenic
mice are nuclear and cytosolic ubiquitinated protein inclusions. IBMPFD has
100% penetrance, but manifests as three
variably presenting phenotypes (i.e.,
weakness, PDB or dementia). The most
prevalent phenotypic feature in IBMPFD
is muscle weakness, which affects >90%
of p97/VCP mutation carriers. This
compares to 50% and 35% of patients
phenotypically having PDB and FTD,
respectively. Affected skeletal muscle has
classic features consistent with a hereditary
IBM. These include muscle degeneration,
protein inclusions and rimmed vacuoles
(RVs) (Fig. 1A). Similarly, skeletal musclerestricted expression of the most common
IBMPFD mutation in transgenic mice
recapitulates these features with animals
acquiring age-associated weakness, accumulation of high molecular weight ubiquitinated proteins, congophilic amyloid
inclusions and vacuolation.
Previous studies suggest that IBMPFD
mutations in p97/VCP cause a defect in
protein degradation. Specifically IBMPFD
mutant-expressing myoblasts accumulate
ubiquitinated proteins and the model
endoplasmic reticulum associated degradation (ERAD) substrate, ∆F508 CFTR,
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Figure 1. IBMPFD patient skeletal muscle tissue processed for (A) congo red histochemistry or (B) TDP-43 immunohistochemistry. (A) Shows an
angular fiber with a large rimmed vacuole (open arrow) and an adjacent congophilic (reddish) sarcoplasmic inclusion (closed arrow). (B) Demonstrates
multiple fibers with TDP-43 inclusions that are perinuclear, subsarcolemmal, sarcoplasmic in healthy appearing, vacuole-containing and degenerating
myofibers. The open arrow denotes a vacuole, and closed arrows denote inclusions.

as cytosolic inclusions. This defect is more
specific for protein aggregates which were
cleared more slowly from IBMPFD mutant
expressing cells and animals. Autophagic
markers such as LC3 and p62 do not
localize to the polyglutamine aggregates
in IBMPFD mutant expressing cells suggesting that IBMPFD mutations in p97/
VCP may affect degradation of aggregated
proteins.
However, a defect in protein aggregate
and ubiquitinated inclusion degradation
fails to account for all of the pathological
features seen in IBMPFD patient tissue,
specifically rimmed vacuoles (RVs). RVs
are accumulations of discontinuous membranous whorls and proteinaceous debris
that are presumed to be autophagic in origin; autophagosomal-lysosomal proteins
such LC3, p62 and LAMP-1/2 localize
to RVs in sporadic and other hereditary
IBMs. In addition, several other vacuolar myopathies are due to a loss in key
autophagic proteins such as LAMP-2 in
Danon disease and the lysosomal enzyme
acid maltase in Pompe disease. Similarly,
mutations in CHMP2B cause a pathologically similar FTD, fronto-temporal lobar
degeneration with ubiquitinated inclusions
(FTLD-U); CHMP2B mutations disrupt
autophagosome maturation in cell culture
and animal models. Finally, mutations in
p62 are the most common cause of PDB
implicating autophagy in PDB as well.
Therefore, we evaluated the autophagosomal/lysosomal system in IBMPFD
mutant-expressing cells, transgenic animals and patient material. LC3 and
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p62 localize to regions of muscle tissue
consistent with RVs in IBMPFD tissue.
Additionally, the autophagosome-associated proteins LC3-II and p62 accumulate
in transgenic mice harboring the most
common IBMPFD mutation, R155H.
This is recapitulated in cells stably expressing IBMPFD mutants and in cells treated
with siRNA oligonucleotides directed
against p97/VCP. These data suggest a
decrease in autophagic flux resulting in an
accumulation of undegraded LC3-II and
p62. To confirm this, we starved control
and p97/VCP-siRNA knockdown cells
for 4 hours and measured the degradation
of LC3-II via immunoblot. LC3-II was
degraded in control cells but remained
stable in p97/VCP knockdown cells identifying a defect in autophagic flux. Similar
results are seen with IBMPFD-mutant
expressing cell lines. These data indicate
that autophagosomes are indeed being
formed, but their degradation and perhaps
maturation is defective. We confirmed this
using a tandemly tagged mRFP-GFP-LC3
fusion protein. We reasoned that accumulation of autophagosomes because of
defective maturation to autolysosomes may
explain the genesis of a RV in IBMPFD.
In agreement with this, ultrastructural
and immunohistochemical analysis of RVs
in IBMPFD myopathy mouse and patient
skeletal muscle demonstrate that RVs are
accumulations of vacuolated structures
that contain non-colocalizing autophagosomal and lysosomal puncta.
Defective autophagosome maturation
explains the accumulation of ubiquitinated
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proteins and RVs in IBMPFD; however,
another striking feature of IBMPFD
muscle and brain tissue that is not easily
explained are TAR DNA binding protein-43 (TDP-43) inclusions (Fig. 1B).
Ubiquitinated inclusions in FTLD-U
and amyotrophic lateral sclerosis contain
TDP-43. In those disorders, TDP-43,
which is normally nuclear, is absent from
the nucleus and instead accumulates as
cytosolic inclusions. The same is true for
IBMPFD patient muscle. Why this occurs
is unknown. We reasoned that an impairment in autophagy may lead to the cytosolic accumulation of TDP-43. Treatment of
cultured U20S cells transiently expressing
an mCherry-TDP-43 fusion protein with
the autophagy inhibitors chloroquine or
bafilomycin A1 results in accumulation
of cytosolic TDP-43 similar to what is
seen when TDP-43 is co-expressed with
IBMPFD mutant or dominant negative p97/VCP. Moreover, aged IBMPFD
mutant mouse and patient muscle specifically accumulates TDP-43 as sarcoplasmic
inclusions. In TDP-43 inclusion bearing
myofibers, TDP-43 is absent from the
nucleus. This same pathology is seen in
mouse muscle when mice are chronically
administered chloroquine for 4 weeks to
pharmacologically block autophagosomelysosome fusion. These data demonstrate
that TDP-43 pathology in IBMPFD is
explained by an impairment in autophagy
conferred by IBMPFD mutant p97/VCP.
The UPS and autophagy have traditionally been thought to serve complementary
yet distinct roles in protein homeostasis.
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Specifically, the UPS selectively degrades
proteins; whereas, autophagy indiscriminately degrades long-lived proteins. Both of
these roles are essential for protein quality
control since the UPS principally degrades
misfolded proteins shortly after their synthesis and autophagy degrades oxidatively
damaged long-lived protein inclusions.
However, it is now clear that these two
systems coordinate protein degradation.
In the setting of normal proteasome activity but impaired autophagy, cells accumulate ubiquitinated protein inclusions,
suggesting that autophagy is also needed
for the degradation of ubiquitinated proteins. Other studies show that impaired
proteasome activity results in a compensatory increase in autophagic activity that is
protective to cells. How these two systems
communicate is unclear.
The chaperone system needed to “triage” degradation-destined proteins to the
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UPS or autophagy is slowly being defined.
This chaperone system would need to
interact with ubiquitinated, misfolded and
aggregated proteins, and additionally with
components of the UPS and autophagy
pathways; sensing the folding state of a
protein, and assessing the integrity of the
UPS and autophagy. Loss or mutation of
this chaperone would presumably lead to
impaired degradation of proteins via both
the UPS and autophagy, accumulation of
ubiquitinated proteins and cell degeneration. Our studies suggest that the chaperone protein, p97/VCP, fulfills many of
these criteria. p97/VCP facilitates the degradation of misfolded proteins through
ERAD and the UPS, and it is necessary
for protein aggregate trafficking and
aggresome formation. Our current study
now implicates p97/VCP in the regulation of autophagy. Depending upon the
state of p97/VCP (i.e., phosphorylated or
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acetylated) or the availability of p97/VCP
cofactors in the cell, we suggest that p97/
VCP is ideally suited to sense the proteostatic state of the cell and coordinates the
degradation of proteins by the the UPS or
autophagy.
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